Pulmatrix Inc PULM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PULM is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.03
- Day Range
- $1.89–1.99
- 52-Week Range
- $1.55–3.09
- Bid/Ask
- $1.85 / $2.20
- Market Cap
- $7.16 Mil
- Volume/Avg
- 6,201 / 14,948
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.98
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 22
- Website
- https://www.pulmatrix.com
Valuation
|
Metric
|
PULM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.40 |
Price/Sales | 0.98 |
Price/Cash Flow | — |
Price/Earnings
PULM
Financial Strength
|
Metric
|
PULM
|
|---|---|
Quick Ratio | 5.14 |
Current Ratio | 5.33 |
Interest Coverage | — |
Quick Ratio
PULM
Profitability
|
Metric
|
PULM
|
|---|---|
Return on Assets (Normalized) | −36.73% |
Return on Equity (Normalized) | −55.08% |
Return on Invested Capital (Normalized) | −50.52% |
Return on Assets
PULM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lthlmtgbzk | Dkv | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vnknhbw | Tjltcs | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rxllkvsk | Fxfsjbw | $103.7 Bil | |
MRNA
| Moderna Inc | Mxwcvcp | Rwjs | $47.9 Bil | |
ARGX
| argenx SE ADR | Mxhptwwkc | Rssp | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Tgsxdywx | Zlfr | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yycgjpqdj | Lshmvl | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nnbpbpgf | Qzkxdp | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pldystpbd | Mksgc | $12.8 Bil | |
INCY
| Incyte Corp | Pdkfzrkzp | Bfszhl | $12.1 Bil |